

## Special Issue

# Genome Engineering Technologies for Diseases

### Message from the Guest Editor

Recent advances in genome engineering have opened new avenues for exploring gene function and developing innovative approaches to understand and treat human diseases. Techniques like gene editing, delivery, and insertional mutagenesis enable precise genome manipulation, driving progress in basic and translational research. These technologies also advance functional genomics through cell-based assays, reporter systems, and in silico tools for large-scale analysis of gene networks and disease pathways. Functional modules have been identified that enhance the versatility of editing platforms. Genome engineering increasingly contributes to advanced therapies like cell therapy and personalized immunotherapy, including CAR-T cells. Integrating experimental and computational methods expands our ability to model diseases and evaluate interventions at cellular levels. This Special Issue showcases genome engineering developments and their disease research applications. We welcome original research and reviews on tool development, computational analysis, functional innovation, and therapeutic applications.

---

### Guest Editor

Dr. Kosuke Ishikawa

Global Consolidated Research Institute for Science Wisdom,  
Comprehensive Research Organization, Waseda University, Tokyo 162-0041, Japan

---

### Deadline for manuscript submissions

31 December 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/250665](https://mdpi.com/si/250665)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).